HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTA

0.00

HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ: ENTA) with a Buy and maintains $20 price target.